Health Care

Ultragenyx insider buying signals confidence amid volatile biotech market. Discover what CEO and senior exec purchases reveal about rare‑disease prospects and stock stability.

Discover how United Therapeutics’ CFO insider trades, robust clinical pipeline, and FDA milestones signal long‑term confidence and value for investors.

BioAge Labs CFO’s fresh buy signals confidence in a fast‑growing longevity‑therapy market, backed by regulatory support and a multi‑target platform.

Procept Biorobotics insider holdings reveal mixed confidence—executive stability amid volatile shares, yet buying signals potential upside in minimally invasive urology.

Belite Bio insider sales by CSO Nathan Mata are a routine liquidity move amid strong regulatory progress and bullish AMD prospects.

Insider buying at NHC signals long‑term confidence: Vicki Dodson adds 4,000 shares at $94.10, boosting her stake amid strategic growth and a 52‑week high of $184.08.

HeartBeam’s insider buying surge after its IPO signals CEO‑candidate Ferrari Richard’s confidence and may hint at future upside, but investors should watch for consistent growth.

Avanos Medical CFO’s April 22 sale: a tax‑withholding move, not a warning. Learn how AIP’s pending acquisition could boost the medical‑device stock’s future.

OneMedNet insider buys signal confidence: executives purchase millions of shares at fair value, hinting at future upside in AI‑driven healthcare analytics.

Insider buying of ProMIS Neurosciences signals confidence in its Phase II clinical progress, precision‑medicine platform, and value‑based reimbursement potential – a bullish cue for investors.